Loper Bright Is Rewriting FDA’s Authority Over Synthetic Biology — Before the Industry Knows It
The Supreme Court's Loper Bright ruling is quietly dismantling FDA's deference-based regulatory hold over synthetic biology, and clinical programs...
Lifestyle Program Improves Brain Health in Cognitive Decline
Interim data from the PREVENTION clinical study report improvements in cerebral blood flow and insulin response among people with...
Maze Therapeutics Announces Sizable $150M Growth Offering
Maze Therapeutics priced a $150 million follow-on, selling 5.54 million shares at $23.50 and issuing 0.85 million pre-funded warrants...
Orion’s ODM-212 Trial for Solid Tumours Starts Phase 1b/2
Orion has opened enrollment for TEADCO, a multicenter, open-label Phase 1b/2 basket trial testing its oral pan-TEAD inhibitor ODM-212...
Phase I Trial of PST-611 for Dry AMD Completes Last Visit
PulseSight has completed follow-up on all six patients in its first-in-human PST-611 study for geographic atrophy secondary to dry...
A New Hope: NP137’s Surging Results in Pancreatic Cancer
Phase 1b data from LAPNET-01 in locally advanced pancreatic ductal adenocarcinoma reported median progression-free survival of 10.85 months, median...
New ATH434 Phase 2 Trial Analysis From Alterity Therapeutics
Alterity’s Phase 2 readout for ATH434 in multiple system atrophy showed slower functional decline versus placebo over 52 weeks...
LB-102 Phase 2 Schizophrenia Trial Results in JAMA Psych
In a four-week, placebo-controlled Phase 2 study in acute schizophrenia, LB-102 achieved statistically significant improvement versus placebo at all...
Maze Therapeutics Reveals Tremendous $150 Million Offering
Maze Therapeutics priced a $150 million underwritten public offering, selling 5.54 million shares at $23.50 and issuing pre-funded warrants...
ASCO 2026 Spotlight: ProstAct Phase 3 Late-Breaking Data
Preliminary safety and dosimetry results from the 36-patient lead-in of Telix’s Phase 3 ProstACT Global study will be delivered...